Open AccessPegvisomant for the Treatment of gsp-Mediated Growth Hormone Excess in Patients with McCune-Albright Syndrome
Author(s) -
Sunday O. Akintoye,
Marilyn H Kelly,
Beth A Brillante,
Natasha Cherman,
Sarah Turner,
John A. Butman,
Pamela Gehron Robey,
Michael T. Collins
Publication year - 2006
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2005-2661
Subject(s) - pegvisomant , endocrinology , medicine , acromegaly , gnas complex locus , crossover study , context (archaeology) , bone remodeling , placebo , hormone , biology , growth hormone , paleontology , biochemistry , alternative medicine , pathology , gene
GH excess affects approximately 20% of the patients with McCune-Albright syndrome (MAS). MAS is caused by sporadic, postzygotic, activating mutations in the GNAS gene, which codes for the cAMP-regulating protein, G(s)alpha (gsp oncogene). These same mutations are found in approximately one third of the sporadic cases of acromegaly.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom